
Sign up to save your podcasts
Or
The Drug Supply Chain Security Act was designed to ensure the safety and integrity of our nation’s drug supply and prevent counterfeit medications from entering the market. In this second of a four-part series, Carolyn Liptak, Eric Marshall, and Josh Bolin share their insights on FDA final DSCSA guidance with host Gretchen Brummel and how member providers can be ready.
Guest speakers:
Carolyn Liptak, MBA, BSPharm
Pharmacy Executive Director
Vizient Center for Pharmacy Practice Excellence
Eric Marshall
Principal at Leavitt Partners
Executive Director of the Partnership for DSCSA Governance
Josh Bolin
Associate Executive Director, Government Affairs and Innovation
National Association of Boards of Pharmacy
Host:
Gretchen Brummel, PharmD, BCPS
Pharmacy Executive Director
Vizient Center for Pharmacy Practice Excellence
Show Notes:
[00:55-02:27] Josh and Eric’s backgrounds
[02:28-03:36] What we need to know for DSCSA implementation on November 27th
[03:37-05:10] NABP view of FDA DSCSA guidance
[05:11-07:27] PDG view of FDA DSCSA guidance
[07:28-08:23] Next steps for DSCSA compliance that our members should be focusing on
[08:24-11:11] Why it is important to have documented policies and procedures to ensure compliance
[11:12-12:28] Where organizations that need help with creating those policies and procedures go
[12:29-15:24] How the 24-hour time frame is defined since medications are not traced within a hospital
[15:25-18:17] DSCSA regulatory responsibilities are shared between the FDA and state boards of pharmacy
[18:18-21:26] How we account for traceability across state lines and what should we expect in the future
[21:27-23:49] Some complexities here especially around 340B medications
[23:50-24:54] Where verification has to occur: data flowing from the manufacturer to the covered entity, but the product is flowing to the actual contracted pharmacy
[24:55-26:30] Last thoughts on how our members can be set for DSCSA
Links | Resources:
Enhanced Drug Distribution Security at the Package Level Under the Drug Supply Chain Security Act (DSCSA)
Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product—Compliance Policies
DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs Guidance for Industry
Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act – Compliance Policies
NABP Links:
https://nabp.pharmacy
https://nabp.pharmacy/pulse
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Google Podcasts
Spotify
Android
RSS Feed
4.6
99 ratings
The Drug Supply Chain Security Act was designed to ensure the safety and integrity of our nation’s drug supply and prevent counterfeit medications from entering the market. In this second of a four-part series, Carolyn Liptak, Eric Marshall, and Josh Bolin share their insights on FDA final DSCSA guidance with host Gretchen Brummel and how member providers can be ready.
Guest speakers:
Carolyn Liptak, MBA, BSPharm
Pharmacy Executive Director
Vizient Center for Pharmacy Practice Excellence
Eric Marshall
Principal at Leavitt Partners
Executive Director of the Partnership for DSCSA Governance
Josh Bolin
Associate Executive Director, Government Affairs and Innovation
National Association of Boards of Pharmacy
Host:
Gretchen Brummel, PharmD, BCPS
Pharmacy Executive Director
Vizient Center for Pharmacy Practice Excellence
Show Notes:
[00:55-02:27] Josh and Eric’s backgrounds
[02:28-03:36] What we need to know for DSCSA implementation on November 27th
[03:37-05:10] NABP view of FDA DSCSA guidance
[05:11-07:27] PDG view of FDA DSCSA guidance
[07:28-08:23] Next steps for DSCSA compliance that our members should be focusing on
[08:24-11:11] Why it is important to have documented policies and procedures to ensure compliance
[11:12-12:28] Where organizations that need help with creating those policies and procedures go
[12:29-15:24] How the 24-hour time frame is defined since medications are not traced within a hospital
[15:25-18:17] DSCSA regulatory responsibilities are shared between the FDA and state boards of pharmacy
[18:18-21:26] How we account for traceability across state lines and what should we expect in the future
[21:27-23:49] Some complexities here especially around 340B medications
[23:50-24:54] Where verification has to occur: data flowing from the manufacturer to the covered entity, but the product is flowing to the actual contracted pharmacy
[24:55-26:30] Last thoughts on how our members can be set for DSCSA
Links | Resources:
Enhanced Drug Distribution Security at the Package Level Under the Drug Supply Chain Security Act (DSCSA)
Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product—Compliance Policies
DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs Guidance for Industry
Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act – Compliance Policies
NABP Links:
https://nabp.pharmacy
https://nabp.pharmacy/pulse
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Google Podcasts
Spotify
Android
RSS Feed
4,321 Listeners
30,734 Listeners
32,071 Listeners
262 Listeners
43,337 Listeners
25,785 Listeners
9,243 Listeners
110,865 Listeners
56,021 Listeners
5,958 Listeners
6,449 Listeners
36 Listeners
21 Listeners
57,297 Listeners
19,373 Listeners